The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease (Q40839501)

24 September 2017

1 reference

title

The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease (English)

1 reference

24 September 2017

0 references

van Hogezand RA

1

1 reference

24 September 2017

Verspaget HW

series ordinal

2

1 reference

24 September 2017

publication date

1 September 1998

1 reference

24 September 2017

1 reference

24 September 2017

volume

56

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

299-305

1 reference

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

24 September 2017

cites work

1 reference

12 December 2020

Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha)

1 reference

12 December 2020

The active form of tumor necrosis factor is a trimer

1 reference

12 December 2020

Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein

1 reference

12 December 2020

Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor .alpha. induced receptor aggregation

1 reference

12 December 2020

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

12 December 2020

The basis of current and future therapy for inflammatory bowel disease

1 reference

12 December 2020

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

12 December 2020

Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.

1 reference

12 December 2020

Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?

1 reference

12 December 2020

Biologic therapy for inflammatory bowel disease

1 reference

12 December 2020

Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55.

1 reference

12 December 2020

Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease

1 reference

12 December 2020

Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells

1 reference

12 December 2020

Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor.

1 reference

12 December 2020

Human tumor necrosis factor. Production, purification, and characterization

1 reference

12 December 2020

Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice

1 reference

12 December 2020

Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses

1 reference

12 December 2020

Taming TNF: strategies to restrain this proinflammatory cytokine

1 reference

12 December 2020

Tumour necrosis factor and Crohn's disease

1 reference

12 December 2020

In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease

1 reference

12 December 2020

10.2165/00003495-199856030-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

1002249403

0 references

Fatcat ID

release_irp3pq7whvh3vm32bfiu7it2je

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/irp3pq7whvh3vm32bfiu7it2je

24 November 2022

mapped directly with Wikidata item

1 reference